GSK moves bioprocessing to UK from India

A focus on efficiency at a GlaxoSmithKline manufacturing plant in the UK has caught the eye of CEO Andrew Witty and prompted him to take an unusual action. He's moving biomanufacturing from India to the drug giant's facilities in Montrose, a town within Scotland's Angus region.

Witty acknowledged the cost and process-efficiency improvements at Montrose, which currently employs 280. "This is a workforce that has rolled with the punches," he says, as quoted in The Courier. The ops team "outmaneuvered" a plant closure, which appeared imminent a few years ago.

Steroid manufacturing is one operation that will return to the town. Locals are hoping that Montrose may become the chosen location for a new biopharma plant being planned by the drug giant.

- here's the story


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.